|
|
Post by peppy on Oct 2, 2017 16:52:11 GMT -5
What me said. The two charts have similar shapes, but are nowhere close to being the same. It's like saying a golf ball and a basketball are the same size because they both happen to be spheres. In particular, look at the y-axis and the units used on one chart vs. the next. When I read figure 1 in that ncbi link, I see fiasp starting at 5 minutes and peaking around 30-40 minutes. What do you see?I see crazy people thinking a subq RAA is faster than afrezza. I see crazy people not considering the tail. (Catch a tiger by the toe.)
Pharmacodynamic effects
Fiasp is a mealtime insulin aspart formulation in which the addition of nicotinamide (vitamin B3) results in a faster initial absorption of insulin compared to NovoRapid.
The onset of action was 5 minutes earlier and time to maximum glucose infusion rate was 11 minutes earlier with Fiasp than with NovoRapid. The maximum glucose-lowering effect of Fiasp occurred between 1 and 3 hours after injection. The glucose–lowering effect during the first 30 minutes (AUCGIR, 0–30 min ) was 51 mg/kg with Fiasp and 29 mg/kg with NovoRapid (Fiasp/NovoRapid ratio: 1.74 [1.47;2.10]95% CI). The total glucose–lowering effect and maximum (GIRmax) glucose–lowering effect were comparable between Fiasp and NovoRapid. Total and maximum glucose–lowering effect of Fiasp increase linearly with increasing dose within the therapeutic dose range.
The duration of action was shorter for Fiasp compared to that of NovoRapid, and lasts for 3–5 hours. 6.1 List of excipients (see the mercury?) Phenol
Metacresol
Glycerol
Zinc acetate
Disodium phosphate dihydrate
Arginine hydrochloride
Nicotinamide (vitamin B3)
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
|
|
|
|
Post by letitride on Oct 2, 2017 17:15:28 GMT -5
I almost wish they can say " The fastest rapid acting insulin that just happens to be inhaled. To say the fastest inhaled inslulin almost makes it sound that it's only the "fastest inhaled insulin ".. no that is not a soft bash.. lol That's the way I say it! |
|
|
|
Post by sayhey24 on Oct 2, 2017 17:42:21 GMT -5
When I read figure 1 in that ncbi link, I see fiasp starting at 5 minutes and peaking around 30-40 minutes. What do you see?I see crazy people thinking a subq RAA is faster than afrezza. I see crazy people not considering the tail. (Catch a tiger by the toe.)
Pharmacodynamic effects
Fiasp is a mealtime insulin aspart formulation in which the addition of nicotinamide (vitamin B3) results in a faster initial absorption of insulin compared to NovoRapid.
The onset of action was 5 minutes earlier and time to maximum glucose infusion rate was 11 minutes earlier with Fiasp than with NovoRapid. The maximum glucose-lowering effect of Fiasp occurred between 1 and 3 hours after injection. The glucose–lowering effect during the first 30 minutes (AUCGIR, 0–30 min ) was 51 mg/kg with Fiasp and 29 mg/kg with NovoRapid (Fiasp/NovoRapid ratio: 1.74 [1.47;2.10]95% CI). The total glucose–lowering effect and maximum (GIRmax) glucose–lowering effect were comparable between Fiasp and NovoRapid. Total and maximum glucose–lowering effect of Fiasp increase linearly with increasing dose within the therapeutic dose range.
The duration of action was shorter for Fiasp compared to that of NovoRapid, and lasts for 3–5 hours. 6.1 List of excipients (see the mercury?) Phenol
Metacresol
Glycerol
Zinc acetate
Disodium phosphate dihydrate
Arginine hydrochloride
Nicotinamide (vitamin B3)
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
I see afrezza officially obsoleted Fiasp today; game; set; match No more excuses. Mike said the factory can handle $2B in sales and said he sees no capacity issue in the near term. I hope he is wrong. |
|
|
|
Post by dreamboatcruise on Oct 2, 2017 17:51:19 GMT -5
I see crazy people thinking a subq RAA is faster than afrezza. I see crazy people not considering the tail. (Catch a tiger by the toe.)
Pharmacodynamic effects
Fiasp is a mealtime insulin aspart formulation in which the addition of nicotinamide (vitamin B3) results in a faster initial absorption of insulin compared to NovoRapid.
The onset of action was 5 minutes earlier and time to maximum glucose infusion rate was 11 minutes earlier with Fiasp than with NovoRapid. The maximum glucose-lowering effect of Fiasp occurred between 1 and 3 hours after injection. The glucose–lowering effect during the first 30 minutes (AUCGIR, 0–30 min ) was 51 mg/kg with Fiasp and 29 mg/kg with NovoRapid (Fiasp/NovoRapid ratio: 1.74 [1.47;2.10]95% CI). The total glucose–lowering effect and maximum (GIRmax) glucose–lowering effect were comparable between Fiasp and NovoRapid. Total and maximum glucose–lowering effect of Fiasp increase linearly with increasing dose within the therapeutic dose range.
The duration of action was shorter for Fiasp compared to that of NovoRapid, and lasts for 3–5 hours. 6.1 List of excipients (see the mercury?) Phenol
Metacresol
Glycerol
Zinc acetate
Disodium phosphate dihydrate
Arginine hydrochloride
Nicotinamide (vitamin B3)
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
I see afrezza officially obsoleted Fiasp today; game; set; match No more excuses. Mike said the factory can handle $2B in sales and said he sees no capacity issue in the near term. I hope he is wrong. Though I'm guessing Fiasp will overtake Afrezza sales levels at some point within a year of it going on sale. |
|
|
|
Post by peppy on Oct 2, 2017 17:57:57 GMT -5
I see afrezza officially obsoleted Fiasp today; game; set; match No more excuses. Mike said the factory can handle $2B in sales and said he sees no capacity issue in the near term. I hope he is wrong. Though I'm guessing Fiasp will overtake Afrezza sales levels at some point within a year of it going on sale. no doubt. Mercury subq is so good for us. Phenol, is a toxic, colourless crystalline solid with a sweet tarry odor that resembles a hospital smell. It is commonly used as an antiseptic and disinfectant. It is active against a wide range of micro-organisms including some fungi and viruses, but is only slowly effective against spores. It has been used to disinfect skin and to relieve itching. Phenol is also used in the preparation of cosmetics including sunscreens, hair dyes, and skin lightening preparations. It is also used in the production of drugs (it is the starting material in the industrial production of aspirin), weedkillers, and synthetic resins. Phenol can be found in areas with high levels of motor traffic, therefore, people living in crowded urban areas are frequently exposed to traffic-derived phenol vapor.
These physicians hittin it out of the park. shhhhh, don't let anyone know how what is really being injected into us.
Toxicity of insulin due to phenol and metacresol www.diabetes.co.uk/forum/threads/toxicity-of-insulin-due-to-phenol-and-metacresol.96246/
Dream, you have been around.... would you take this stuff if you had a choice?
|
|
|
|
Post by dreamboatcruise on Oct 2, 2017 18:10:12 GMT -5
Though I'm guessing Fiasp will overtake Afrezza sales levels at some point within a year of it going on sale. no doubt. Mercury subq is so good for us. Phenol, is a toxic, colourless crystalline solid with a sweet tarry odor that resembles a hospital smell. It is commonly used as an antiseptic and disinfectant. It is active against a wide range of micro-organisms including some fungi and viruses, but is only slowly effective against spores. It has been used to disinfect skin and to relieve itching. Phenol is also used in the preparation of cosmetics including sunscreens, hair dyes, and skin lightening preparations. It is also used in the production of drugs (it is the starting material in the industrial production of aspirin), weedkillers, and synthetic resins. Phenol can be found in areas with high levels of motor traffic, therefore, people living in crowded urban areas are frequently exposed to traffic-derived phenol vapor.
These physicians hittin it out of the park. shhhhh, don't let anyone know how what is really being injected into us.
Toxicity of insulin due to phenol and metacresol www.diabetes.co.uk/forum/threads/toxicity-of-insulin-due-to-phenol-and-metacresol.96246/
Dream, you have been around.... would you take this stuff if you had a choice?
I live in a crowded urban area, so I guess I'm already making a lifestyle choice that involves phenol. If I ever develop T2, my preferred choice would of course be Afrezza... but that would be primarily for the fast action and avoiding injection. |
|
|
|
Post by od on Oct 2, 2017 19:16:15 GMT -5
I see afrezza officially obsoleted Fiasp today; game; set; match No more excuses. Mike said the factory can handle $2B in sales and said he sees no capacity issue in the near term. I hope he is wrong. Though I'm guessing Fiasp will overtake Afrezza sales levels at some point within a year of it going on sale. ...within a week? |
|
|
|
Post by brewguy on Oct 2, 2017 19:50:55 GMT -5
Overall I would say today's news was neutral at best (leaning towards bad). Afrezza failed to get the most important (or at least most anticipated) change to "ultra rapid". Imo just being able to show oneset times doesn't change much. This info was already accessible to anyone who did 5 minutes of research. A label of "ultra rapid" would put afrezza in a class by itself giving prescribers more ammo to justify rxing it.
On top of that, Mike still refused to fully address the insolvency issues. Mike seems too cautious to appease investors but not what's best for the company. We will see shortly if he's either a genius or has no idea what he is doing.
|
|
|
|
Post by digger on Oct 2, 2017 20:13:04 GMT -5
When I read figure 1 in that ncbi link, I see fiasp starting at 5 minutes and peaking around 30-40 minutes. What do you see?I see crazy people thinking a subq RAA is faster than afrezza. I see crazy people not considering the tail. (Catch a tiger by the toe.)
Pharmacodynamic effects
Fiasp is a mealtime insulin aspart formulation in which the addition of nicotinamide (vitamin B3) results in a faster initial absorption of insulin compared to NovoRapid.
The onset of action was 5 minutes earlier and time to maximum glucose infusion rate was 11 minutes earlier with Fiasp than with NovoRapid. The maximum glucose-lowering effect of Fiasp occurred between 1 and 3 hours after injection. The glucose–lowering effect during the first 30 minutes (AUCGIR, 0–30 min ) was 51 mg/kg with Fiasp and 29 mg/kg with NovoRapid (Fiasp/NovoRapid ratio: 1.74 [1.47;2.10]95% CI). The total glucose–lowering effect and maximum (GIRmax) glucose–lowering effect were comparable between Fiasp and NovoRapid. Total and maximum glucose–lowering effect of Fiasp increase linearly with increasing dose within the therapeutic dose range.
The duration of action was shorter for Fiasp compared to that of NovoRapid, and lasts for 3–5 hours. 6.1 List of excipients (see the mercury?) Phenol
Metacresol
Glycerol
Zinc acetate
Disodium phosphate dihydrate
Arginine hydrochloride
Nicotinamide (vitamin B3)
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
No, I'm afraid I don't see any mercury. |
|
|
|
Post by mytakeonit on Oct 2, 2017 20:22:06 GMT -5
Overall I would say today's news was neutral at best (leaning towards bad). Afrezza failed to get the most important (or at least most anticipated) change to "ultra rapid". Imo just being able to show oneset times doesn't change much. This info was already accessible to anyone who did 5 minutes of research. A label of "ultra rapid" would put afrezza in a class by itself giving prescribers more ammo to justify rxing it. On top of that, Mike still refused to fully address the insolvency issues. Mike seems too cautious to appease investors but not what's best for the company. We will see shortly if he's either a genius or has no idea what he is doing. Okay DBC ... I take back what I said to you. You can smack this guy down anytime you want. And brew breath ... you can say that after only being on the board since August?!!! LOL |
|
|
|
Post by peppy on Oct 2, 2017 20:41:58 GMT -5
I see crazy people thinking a subq RAA is faster than afrezza. I see crazy people not considering the tail. (Catch a tiger by the toe.)
Pharmacodynamic effects
Fiasp is a mealtime insulin aspart formulation in which the addition of nicotinamide (vitamin B3) results in a faster initial absorption of insulin compared to NovoRapid.
The onset of action was 5 minutes earlier and time to maximum glucose infusion rate was 11 minutes earlier with Fiasp than with NovoRapid. The maximum glucose-lowering effect of Fiasp occurred between 1 and 3 hours after injection. The glucose–lowering effect during the first 30 minutes (AUCGIR, 0–30 min ) was 51 mg/kg with Fiasp and 29 mg/kg with NovoRapid (Fiasp/NovoRapid ratio: 1.74 [1.47;2.10]95% CI). The total glucose–lowering effect and maximum (GIRmax) glucose–lowering effect were comparable between Fiasp and NovoRapid. Total and maximum glucose–lowering effect of Fiasp increase linearly with increasing dose within the therapeutic dose range.
The duration of action was shorter for Fiasp compared to that of NovoRapid, and lasts for 3–5 hours. 6.1 List of excipients (see the mercury?) Phenol
Metacresol
Glycerol
Zinc acetate
Disodium phosphate dihydrate
Arginine hydrochloride
Nicotinamide (vitamin B3)
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections
No, I'm afraid I don't see any mercury. Digger, I was WRONG. Thank you.
(Mercury is an ingredient in dental amalgams. Thiomersal (called Thimerosal in the United States) is an organic compound used as a preservative in vaccines, though this use is in decline.[48] Thiomersal is metabolized to ethyl mercury. Although it was widely speculated that this mercury-based preservative could cause or trigger autism in children, scientific studies showed no evidence supporting any such link.[49] Nevertheless, thiomersal has been removed from, or reduced to trace amounts in all U.S. vaccines recommended for children 6 years of age and under, with the exception of inactivated influenza vaccine.[50]) Being saved for vaccines. I am sorry about the mistake.
|
|
|
|
Post by mydogskip on Oct 2, 2017 21:12:55 GMT -5
Overall I would say today's news was neutral at best (leaning towards bad). Afrezza failed to get the most important (or at least most anticipated) change to "ultra rapid". Imo just being able to show oneset times doesn't change much. This info was already accessible to anyone who did 5 minutes of research. A label of "ultra rapid" would put afrezza in a class by itself giving prescribers more ammo to justify rxing it. On top of that, Mike still refused to fully address the insolvency issues. Mike seems too cautious to appease investors but not what's best for the company. We will see shortly if he's either a genius or has no idea what he is doing. Bingo! Today's news was far from a game changer. What Mnkd needs is money to weather the storm and hope that their sales people can convince doctors to prescribe it and insurance companies to support it. Otherwise, MNKD will end up being a NICHE drug manufacturer. |
|
|
|
Post by brewguy on Oct 2, 2017 21:46:01 GMT -5
Overall I would say today's news was neutral at best (leaning towards bad). Afrezza failed to get the most important (or at least most anticipated) change to "ultra rapid". Imo just being able to show oneset times doesn't change much. This info was already accessible to anyone who did 5 minutes of research. A label of "ultra rapid" would put afrezza in a class by itself giving prescribers more ammo to justify rxing it. On top of that, Mike still refused to fully address the insolvency issues. Mike seems too cautious to appease investors but not what's best for the company. We will see shortly if he's either a genius or has no idea what he is doing. Okay DBC ... I take back what I said to you. You can smack this guy down anytime you want. And brew breath ... you can say that after only being on the board since August?!!! LOL Okay....because I am being a realist? Please tell me how you are not disappointment by the denied label change? How will being able to put a printed table of onset times change much? Please elaborate other than getting upset that I said something "mean" about MNKD. |
|
|
|
Post by dreamboatcruise on Oct 2, 2017 21:52:16 GMT -5
Overall I would say today's news was neutral at best (leaning towards bad). Afrezza failed to get the most important (or at least most anticipated) change to "ultra rapid". Imo just being able to show oneset times doesn't change much. This info was already accessible to anyone who did 5 minutes of research. A label of "ultra rapid" would put afrezza in a class by itself giving prescribers more ammo to justify rxing it. On top of that, Mike still refused to fully address the insolvency issues. Mike seems too cautious to appease investors but not what's best for the company. We will see shortly if he's either a genius or has no idea what he is doing. Bingo! Today's news was far from a game changer. What Mnkd needs is money to weather the storm and hope that their sales people can convince doctors to prescribe it and insurance companies to support it. Otherwise, MNKD will end up being a NICHE drug manufacturer. Seems like the market wasn't freaked out by the prospect of 22 mil shares hitting the market. I feel quite positive about today. Wish Mike wouldn't continue to tease, such as repeatedly mentioning RLS with no indication of why we should consider it meaningful. I prefer something concrete such as large PBM being added for 2018 formulary without detail of who vs this mentioning of who but with absolutely no indication of the what. But that probably can be chalked up to a my own peeve. Don't tease me Mike! |
|
|
|
Post by obamayoumama on Oct 2, 2017 22:27:08 GMT -5
Overall I would say today's news was neutral at best (leaning towards bad). Afrezza failed to get the most important (or at least most anticipated) change to "ultra rapid". Imo just being able to show oneset times doesn't change much. This info was already accessible to anyone who did 5 minutes of research. A label of "ultra rapid" would put afrezza in a class by itself giving prescribers more ammo to justify rxing it. On top of that, Mike still refused to fully address the insolvency issues. Mike seems too cautious to appease investors but not what's best for the company. We will see shortly if he's either a genius or has no idea what he is doing. Ouch, nice try shortie |
|
